Does McKesson (MCK) Trade Below Fair Value On Cash Flow?

McKesson has logged a powerful share price run in recent years, which naturally raises a question for anyone looking at the stock today. Are the cash flows of this healthcare distributor strong and resilient enough to support where the market now values the business?

• Over the past 5 years the stock has returned 339.6%, which puts the spotlight squarely on whether that share price journey aligns with the cash the company is expected to produce.
• The business model is built around large scale pharmaceutical distribution and related services, which can support sizeable and relatively steady cash generation that investors often compare against the current valuation.
• What if you looked at McKesson through its earnings instead? See what McKesson's 24.4x P/E says about the price.

For investors, the debate is whether McKesson's recent share price level is appropriately backed by the cash flows implied in a Discounted Cash Flow (DCF) style intrinsic value estimate.

If you are weighing McKesson against other opportunities that hinge on cash generation and valuation, it can help to compare it with companies surfaced by our 26 high quality undervalued stocks

Does McKesson Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) method used here estimates what McKesson might return to shareholders in future cash, then discounts those figures back to today. On recent numbers the group produced last twelve month free cash flow of about $6.0b, which gives the model a fairly substantial base to work from rather than relying on hypothetical turnarounds.

Analysts contributing to this DCF expect McKesson to continue generating multi billion dollar free cash flows, with forecasts extending into the 2030s before transitioning into a steadier long term phase. When those future streams are discounted and combined, the model suggests an intrinsic value that sits substantially above the current share price of $960.56. For readers who want to see how that gap looks in full detail, including the projected cash flows that underpin it, the complete DCF output is available through the tool linked here. Find out what McKesson could be worth using our Discounted Cash Flow (DCF) estimate.

The McKesson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the McKesson valuation puzzle leaves off by spelling out which assumptions about growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than it is today on the market. They sit on the Community page so you can see how those storylines line up with new data.

Rather than focusing on a single multiple or model output, each Narrative lays out the key drivers behind its view of McKesson's worth so you can compare those expectations with actual results as they are reported.

One of the top community narratives on McKesson: roughly fairly valued

"Analysts expect McKesson to keep shifting its business mix toward oncology, specialty distribution, and technology-enabled services..."

Discover why this Narrative puts McKesson at roughly fairly valued.

One more McKesson check that belongs beside the cash flow math

Valuation models only tell part of the story, because the real-world outcomes depend heavily on who is steering McKesson and how their incentives are structured. See who runs McKesson and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com